EN DE

Nova Leap Health Corp (NLH) Fair Value & Analysis

Healthcare · CA · Market cap C$32.3M

NL Nova Leap Health Corp NLH · V
PriceC$0.3800
Fair ValueC$0.2100
Upside-44.7%
Quality62/100
Watch Nova Leap Health Corp for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 0.7% net margin
Low debt · generates free cash flow
Mixed vs. peers (5/12)
Narrow moat 28/100
Evidence: Medium Range C$0.1600 – C$0.2600 Share as image

Fair value as of: Jul 19, 2026

From 13 valuation models · updated 23 days ago

Fair value updated Jul 19, 2026, revised from C$0.3100 to C$0.2100 (−32.3%) since Jun 24, 2026.

A solid business, but screening 45% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (C$0.2600). The favourable scenario is already priced in.
  • Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

C$0.9800 C$0.1250 Fair Value C$0.2100 Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.

How to read this chart

60‑month range C$0.1250 – C$0.9800 · fair‑value band C$0.1600 – C$0.2600 · the C$0.3800 price screens above the C$0.2100 fair value. Dashed = 300-day average. As of Jul 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Nova Leap Health Corp (NLH) currently trades at C$0.3800, while our model-based Fair Value estimate is C$0.2100, implying the stock looks roughly 44.7% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Nova Leap Health Corp generated revenue of C$32.2M at a net margin of 0.7%. Revenue grew 10.7% year over year. It earns a return on equity of 1.1%. Fundamentals as of Jul 19, 2026

Our scenario range runs from C$0.1600 (bear case) to C$0.2600 (bull case); at C$0.3800, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 73% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -45%, NLH screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF C$0.2100 C$0.3400 C$0.5300 80
Rev-Margin DCF C$0.1900 C$0.3000 C$0.5400 74
ROIC Compounder C$0.1000 C$0.1100 C$0.1200 72
All 13 models by family
DCF Models
FCF DCF C$0.2300 C$0.3100 C$0.5600 38
5Y Revenue Exit C$0.1700 C$0.2700 C$0.4600 39
5Y EBITDA Exit C$0.2400 C$0.4100 C$0.7300 41
10Y Revenue Exit C$0.1900 C$0.3400 C$0.4300 36
10Y EBITDA Exit C$0.2400 C$0.4700 C$0.8800 37
Earnings-Based
EPV C$0.1000 C$0.1100 C$0.1200 59
Multiples
EV/EBIT C$0.1800 C$0.2300 C$0.2900 53
EV/EBITDA C$0.2500 C$0.3300 C$0.4000 54
EV/Revenue C$0.1300 C$0.1800 C$0.2300 43
Asset-Based
NCAV (Graham) C$0.1100 C$0.1500 C$0.2200 50
Growth DCF
Growth DCF C$0.2100 C$0.3400 C$0.5300 80
Rev-Margin DCF C$0.1900 C$0.3000 C$0.5400 74
Economic Profit
ROIC Compounder C$0.1000 C$0.1100 C$0.1200 72

Widest divergence: DCF Models (C$0.3400) versus Earnings-Based (C$0.1100). Highest evidence: Growth DCF (80).

Notify me when NLH reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) C$32.2M
Revenue growth (YoY) +10.7%
Net margin 0.7%
Return on equity 1.1%
Free cash flow C$1.6M FY2025
Operating margin 3.7%
More key figures
EPS growth (YoY) -41.0%
Net debt C$514K FY2025

Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 62/100

Of which business quality 62 · Market factors (momentum, volatility) 50

Profitability 47
Margins and returns on capital today
Quality Growth 51
Are margins and returns improving?
Cashflow 54
Earnings quality: real cash, not paper profit
Fin. Strength 73
Balance sheet, leverage, solvency risk
Investment 99
Disciplined investing over empire-building
Low Volatility 7
Calm price path (market factor)
Momentum 66
Price trend over the last 3–12 months (market factor)
52W Momentum 73
Distance to the 52-week high (market factor)
Net Issuance 61
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Nova Leap Health Corp., together with its subsidiaries, provides home-based and community-based healthcare services in the United States and Canada.

Full company description

Nova Leap Health Corp., together with its subsidiaries, provides home-based and community-based healthcare services in the United States and Canada. It offers home and home health care services, including dementia care, companionship, personal and skilled nursing care, respite care, palliative care, care management, cooking and meal preparation, light housekeeping, daily living activities, transportation, medication reminders, and medication administration by nursing staff. The company provides its services through private homes, assisted living communities, hospitals, nursing homes, hospice, and rehabilitation centers. Nova Leap Health Corp. was incorporated in 2015 and is headquartered in Halifax, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Nova Leap Health Corp reported revenue of C$31.5M in FY2025 versus C$21.3M in FY2021, a compound +10.3%/yr. Reported net income was −C$190K in FY2025.

Growth Quality 73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
C$31.5M
Latest YoY
+22.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.7%
Avg. growth/yr (9Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+134.6%
Revenue +10.3%/yr
FY21 C$21.3M
FY22 C$28.2M
FY23 C$26.2M
FY24 C$25.8M
FY25 C$31.5M
Net income
FY21 C$1.8M
FY22 −C$836K
FY23 −C$1.1M
FY24 C$1.4M
FY25 −C$190K

NLH screens 45% overvalued. Compare with HCA Healthcare, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Nova Leap Health Corp Fair Value". https://www.fairvalue-calculator.com/stock/NLH

Peer Group

Medical Care Facilities · 261 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 62 · Above median
Fair Value upside −45% · Bottom 25%
Return on equity (TTM) 1% · Below median
Return on assets 4% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 4% · Below median
Revenue growth 11% · Above median
Debt / equity 0.01× · Lower than 75% of peers

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/B 1.22× · Cheaper than median
P/S (TTM) 0.72× · Cheaper than median
P/FCF 14.9× · Pricier than 75% of peers
EV/EBITDA 12.4× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 23
FUTURE 54 · sector 24
PAST 5 · sector 30
HEALTH 100 · sector 90
DIVIDEND 0 · sector 38

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare Nova Leap Health Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Nova Leap Health Corp (NLH) overvalued or undervalued?
As of Jul 19, 2026, our model estimates a fair value of C$0.2100 versus a price of C$0.3800, about −45% (overvalued).
What is the fair value of NLH?
Our model-based fair value for Nova Leap Health Corp is C$0.2100 (as of Jul 19, 2026), built from audited fundamentals. The current price is C$0.3800.
What is the quality score of NLH?
Nova Leap Health Corp has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Nova Leap Health Corp (NLH)?
Nova Leap Health Corp reported trailing-twelve-month revenue of about C$32.2M (latest available figure, as of Jul 19, 2026).
What is the net profit margin of NLH?
The net profit margin of Nova Leap Health Corp is about 0.7%, meaning it keeps roughly 0.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Nova Leap Health Corp and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.